CompletedPhase 4NCT02532569
Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
Studying Encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boryung Pharmaceutical Co., Ltd
- Principal Investigator
- HJ Jung, MDBoryung Pharmaceutical Company
- Intervention
- Japanese encephalitis vaccine(biological)
- Enrollment
- 94 enrolled
- Eligibility
- 6-7 years · All sexes
- Timeline
- 2015 – 2016
Study locations (9)
- Wonju Sevrance Christian Hospital, Wŏnju, Gangwon-do, South Korea
- Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, South Korea
- Gachon University Gil Medical Center, Incheon, South Korea
- Inha University Hospital, Incheon, South Korea
- Ewha Womans University Mokdong Hospital, Seoul, South Korea
- Korea Cancer Center Hospital, Seoul, South Korea
- KyungHee University Hospital, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- Seoul National University Hospital, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02532569 on ClinicalTrials.govOther trials for Encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07511049Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot StudyNational Institute of Neurological Disorders and Stroke (NINDS)
- ACTIVE NOT RECRUITINGNCT07554261Clinical Features and Outcomes of VZV CNS InfectionsKocaeli University
- RECRUITINGNCT07332234Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral PathologiesSpitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
- ACTIVE NOT RECRUITINGNCT06820060Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel PlusQIAGEN Gaithersburg, Inc
- ACTIVE NOT RECRUITINGPHASE2NCT06899802A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineBavarian Nordic
- RECRUITINGPHASE1, PHASE2NCT06680128A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsSK Bioscience Co., Ltd.
- RECRUITINGNCT06368648CoMind Early Feasibility StudyCoMind Technologies Limited
- ACTIVE NOT RECRUITINGPHASE4NCT06678373Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasLiaoning Chengda Biotechnology CO., LTD